RhumbLine Advisers
WHWK

RhumbLine Advisers’s Whitehawk Therapeutics WHWK Stock Holding History

RhumbLine Advisers’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,487
Closed -$13.8K – 4356
2024
Q2 		$13.8K Sell
9,487
-15,899
-63% -$29.5K ﹤0.01% 3933
2024
Q1 		$59.4K Buy
25,386
+589
+2% +$1.14K ﹤0.01% 3591
2023
Q4 		$50.1K Hold
24,797
– – ﹤0.01% 3633
2023
Q3 		$120K Buy
24,797
+1,249
+5% +$7.26K ﹤0.01% 3396
2023
Q2 		$161K Buy
23,548
+4,245
+22% +$33K ﹤0.01% 3345
2023
Q1 		$140K Buy
19,303
+814
+4% +$8.7K ﹤0.01% 2812
2022
Q4 		$237K Buy
18,489
+424
+2% +$5.54K ﹤0.01% 2748
2022
Q3 		$255K Buy
18,065
+1,069
+6% +$14K ﹤0.01% 2802
2022
Q2 		$209K Buy
+16,996
New +$252K ﹤0.01% 2914

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's WHWK Position: Q3 2024 in Review

RhumbLine Advisers sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 9,487 shares — an estimated $13.8K sold.

RhumbLine Advisers first reported a position in WHWK in Q2 2022 and held it in 9 quarters. The position peaked at $255K in Q3 2022. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • RhumbLine Advisers reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 9,487 Whitehawk Therapeutics shares in Q3 2024, an estimated $13.8K.
  • RhumbLine Advisers first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 9 quarters.
  • RhumbLine Advisers's Whitehawk Therapeutics position peaked at $255K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.